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Introduction: For patients with resectable hepatocellular carcinoma (HCC), hepatectomy remains one 
of the best treatment options to provide long-term survival. However, more than 50% of the patients 
have unresectable disease upon diagnosis even though there are no distant metastases. Transarterial 
chemoembolization (TACE) is a well-established treatment option that offers a palliative survival benefit 
for this group of patients. A better treatment for unresectable HCC has been sought after. There is some 
evidence that transarterial radioembolization (TARE) with the agent yttrium-90 produces encouraging 
outcomes, especially in patients with portal vein tumor thrombus. This study aims to analyze the outcomes 
of TARE at our center.
Methods: From August 2009 to April 2013, 16 patients underwent TARE at our center. Sixteen patients 
with similar tumor characteristics were selected to undergo TACE alone for comparison. A retrospective 
analysis of the prospectively collected data of the patients was conducted. Only patients with newly diagnosed 
primary tumors were included in this study.
Results: The median survival for patients having TARE was 19.9 versus 14.0 months in the TACE 
group (P=0.615). There was no difference in terms of tumor response according to the modified Response 
Evaluation Criteria in Solid Tumors (mRECIST) (P=0.632). The 1-, 2- and 3-year survival rates in the 
TARE group were 80.0%, 30.5% and 20.3% respectively. The 1-year survival in the TACE group was 58.3% 
(P=0.615). For patients who had major vascular invasion (eight in each group), the 1- and 2-year survival 
rates in the TARE group were 62.5% and 15.6% respectively, while the 1-year survival in the TACE group 
was 35.0% (P=0.664).
Conclusions: The two groups showed similar results in terms of tumor response and overall survival 
benefit. TARE might provide a survival benefit for patients with major vessel invasion.
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Introduction
Hepatocellular carcinoma (HCC) is a major healthcare 
problem, particularly in Asia where hepatitis B is prevalent. 
Some HCC patients are unable to undergo surgery due to 
underlying comorbidities, poor liver function reserve, or 
advanced tumor status (1,2). Transarterial chemoembolization 
(TACE) is a well-established palliative treatment option 
(3-5), but it is not suitable for all inoperable HCC patients 
as it also carries the risk of complications (6). Child-Pugh C 
cirrhosis, biliary obstruction, severe encephalopathy and main 
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portal vein tumor thrombosis are contraindications to TACE. 
Minor complications include postembolization syndrome, 
which occurs in up to 90% of patients (7), while hepatic 
decompensation may occur in up to 20% of patients (8). 
Targeted therapy such as sorafenib treatment only offers a 
limited survival benefit (9,10) but is associated with significant 
adverse effects including skin-related toxicities, diarrhea, 
neutropenic fever, hypertension, and proteinuria, as well as 
life-threatening complications such as thromboembolism and 
bowel perforation. [Nexavar (package insert), Wayne, NJ: 
Bayer HealthCare Pharmaceuticals Inc; 2009] [Launay-Vacher 
V, Deray G. Hypertension and proteinuria: a class-effect of 
antiangiogenic therapies. Anticancer Drugs. 2009]. A better 
treatment for unresectable HCC has been sought after. There 
is some evidence that transarterial radioembolization (TARE) 
using yttrium-90 yields some encouraging results (11-14), 
especially in patients who suffer from portal vein tumor 
thrombus, which is a contraindication to TACE (2,15,16).
TARE and TACE have been shown to have similar 
toxicity and survival outcome (17-19). Some patients having 
TARE were found to have their disease downstaged and 
better disease-free survival (20). This study compares the 
effects of TARE and TACE in patients with inoperable 
advanced HCC at our center.
Patients and methods
From August 2009 to April 2013, 16 patients underwent 
TARE at  Queen Mary Hospital .  All  of  them had 
unresectable advanced HCC. They were chosen to undergo 
TARE according to the following five criteria: (I) their 
TACE treatment had failed or they had a contraindication 
to TACE (e.g., portal vein thrombosis); (II) their life 
expectancy was >3 months; (III) their pre-treatment 99Tc 
macroaggregated albumin (MAA) scans showed <30 Gy 
radiation exposure to the lung (percentage of lung 
shunting <20%) or no significant extrahepatic deposition 
of 99Tc MAA in the gastrointestinal tract that could not 
be corrected by the catheter embolization technique; (IV) 
they had a serum total bilirubin level of <34 mmol/L; (V) 
they had no angiographic contraindications (e.g., renal 
insufficiency, thrombocytopenia/coagulopathy, contrast 
nephropathy). Portal vein thrombosis was not regarded 
as a contraindication to TARE. In fact there were case 
reports of recanalization of portal vein thrombosis due to 
tumor invasion after TARE (21). TARE was conducted 
by the Department of Radiology in conjunction with the 
Department of Clinical Oncology.
A retrospective analysis of the prospectively collected 
data of the patients was conducted. A matched cohort of 
16 patients with similar tumor characteristics in the same 
period were selected to undergo TACE alone. Matching 
criteria included demographic characteristics, comorbidities, 
tumor size, tumor number, and the presence of major 
vascular invasion. Imaging studies were reviewed and 
clinical outcomes were abstracted from the medical records. 
We arbitrarily used “5 cm” to differentiate large and small 
tumors, and a tumor number of three was used as the cutoff 
to categorize the patients into two groups. The two groups 
had similar periods of follow-up.
These patients were considered inoperable after careful 
evaluation of their tumor status. The primary endpoint of 
the study was tumor response according to the modified 
Response Evaluation Criteria in Solid Tumors (mRECIST). 
The secondary endpoint was survival. Only patients who 
were newly diagnosed of HCC were included in the study. 
All of them were carriers of hepatitis B virus. The diagnoses 
of HCC fulfilled the guidelines published in the American 
Association for the Study of Liver Disease in 2010 (2). 
Triphasic computed tomography or magnetic resonance 
imaging, or both, was used for diagnosis. This study 
was overseen by the Institutional Review Board of The 
University of Hong Kong. Informed consent by the patients 
was obtained before recruitment.
Procedures
TACE treatment
Before treatment, the patients were hydrated and blood tests 
were conducted for complete blood picture, liver and renal 
functions, clotting profile, and alpha-fetoprotein level. Fresh 
frozen plasma or platelet concentrate was given accordingly. 
Intravenous amoxicillin-clavulanic acid (1.2 gm), mannitol 
(20 gm), tropisetron (5 mg) and pantoprazole (40 mg) were 
prescribed before the procedure. The femoral artery was 
catheterized under local anesthesia. Hepatic arteriography 
and superior mesenteric arterial portovenography were 
performed to define the sizes and locations of tumor nodules 
and to exclude occlusion of the main portal vein. The right 
or left hepatic artery feeding the tumor was super-selectively 
catheterized. An emulsion was prepared by mixing cisplatin 
(1 mg/mL) with lipiodol in a volume ratio of 1 to 1. Various 
amounts of the emulsion, up to a maximum of 60 mL 
(containing 30 mg of cisplatin), were injected slowly under 
fluoroscopic monitoring according to the size of the tumor 
and the arterial blood flow. If the tumor involved both lobes of 
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the liver or if super-selective catheterization was not possible, 
the emulsion was injected into the proper hepatic artery 
distal to the origin of the gastroduodenal artery. This was 
followed by embolization with small gelatin-sponge pellets 
of a diameter of 1 mm mixed with 40 mg of gentamicin. 
After the procedure, oral amoxicillin-clavulanic acid 
(375 mg 3 times per day) and pantoprazole (40 mg per day) 
were administered for 3 days. Discharge from the hospital was 
decided according to individual patients’ clinical status. TACE 
was repeated every 2 to 3 months. If poor liver function (serum 
total bilirubin level >50 μmol/L or presence of ascites), poor 
renal function (serum creatinine level >120 μmol/L), vascular 
contraindications, severe adverse effects or progressive disease 
developed, TACE was withheld or discontinued.
Pre-TARE imaging evaluation
Every patient underwent pretreatment mesenteric 
angiography and 99 Tc MAA scanning to look at the vascular 
anatomy in relation to the tumor as well as the degree 
of pulmonary shunting. Pulmonary shunting of ≥20% 
might result in toxicity and complications due to systemic 
distribution and absorption of radioactive substances during 
TARE. The problem could be reduced by embolizing the 
non-target vessels to minimize the flow of yttrium particles 
into the uninvolved liver and extrahepatic tissues.
Yttrium-90 microsphere treatment for TARE
Before treatment, the patients were hydrated and blood 
tests were conducted for complete blood picture, liver and 
renal functions, clotting profile, and alpha-fetoprotein 
level. Fresh frozen plasma or platelet concentrate was 
given accordingly. Intravenous amoxicillin-clavulanic 
acid (1.2 gm), mannitol (20 gm), tropisetron (5 mg) and 
pantoprazole (40 mg) were prescribed before the procedure. 
The femoral artery was catheterized under local anesthesia. 
Hepatic arteriography and superior mesenteric arterial 
portovenography were performed. The right or left hepatic 
artery feeding the tumor was super-selectively catheterized. 
Yttrium-90 resin microspheres were then administered into 
the feeding artery. After the procedure, oral amoxicillin-
clavulanic acid (375 mg 3 times per day) and pantoprazole 
(40 mg per day) were administered for 3 days. Discharge 
from the hospital was decided according to individual 
patients’ clinical status.
Posttreatment assessment
All patients who had undergone TACE or TARE were 
subjected to computed tomography or magnetic resonance 
imaging in 2 months’ time after the initial intervention to 
assess the treatment effect. The mRECIST were adopted 
to assess the treatment responses, which were classified as 
complete response, partial response, progressive disease, 
and stable disease. Complete response was defined as the 
disappearance of intratumoral arterial enhancement in 
all target lesions. Partial response was defined as an at 
least 30% decrease in the sum of diameters of viable (with 
enhancement in the arterial phase) target lesions, with the 
baseline sum of the diameters of target lesions taken as 
reference. Progressive disease was defined as an at least 20% 
increase in the sum of the diameters of viable target lesions, 
with the smallest sum of the diameters of viable target 
lesions recorded since the beginning of treatment taken as 
reference. Stable disease was defined as any case that did not 
qualify as partial response or progressive disease (22).
Imaging analysis
Imaging interpretations were performed by two consultant 
radiologists with special interests in hepatobiliary imaging. 
All baseline imaging results were calculated, and the results 
of the reassessment imaging performed after 2 months were 
studied. An imaging was performed 2 months after the 
first treatment, and another imaging was performed after 
the second treatment. If no further treatment was given, 
subsequent scans were performed at 90-day intervals. The 
mRECIST were used to assess treatment responses (22).
Follow-up
Every patient was followed up at our clinic 4 weeks after 
discharge. Blood tests for complete blood picture, liver and 
renal functions, clotting profile and alpha-fetoprotein level 
were conducted the day before to assess the patient’s clinical 
status and well-being after the intervention. Follow-up 
appointments were arranged after reassessment computed 
tomography scans had been done. Depending on the patient’s 
response to treatment, further TARE or TACE might be 
given. If progressive disease was evidenced on computed 
tomography, further treatment would not be given.
Statistical analysis
All survival analyses were calculated from the dates of the 
first TACE or TARE treatments. Pearson’s chi-squared 
test or Fisher’s exact test was used for categorical variables. 
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Continuous variables were expressed as medians and ranges 
and were compared by the Mann-Whitney U test. The 
Kaplan-Meier method was used for overall survival analysis, 
and the log-rank test was used for survival comparison. 
P values <0.05 were considered statistically significant. 
The computer software SPSS, version 21.0, was used for 
statistical analyses.
Results
In the study period, 16 patients underwent TARE (the 
TARE group). All of them had unresectable advanced 
HCC. A matched cohort of 16 patients with similar tumor 
characteristics in the same period were selected to undergo 
TACE alone (the TACE group). The two groups of patients 
were matched according to tumor size (if a patient had 
two or more tumors, the size of the largest tumor was 
considered), tumor number, and the presence of tumor 
invasion of a major branch of the portal or hepatic vein. 
The two groups of patients had the same tumor status. The 
two groups were similar in terms of patient characteristics, 
pretreatment liver function, and comorbidity (Table 1). 
Table 2 compares the two groups in terms of tumor 
characteristics, and Table 3 compares them in terms of 
hospital mortality, complication, and treatment responses. 
All the patients underwent both treatment procedures safely.
The median overall survival duration was 19.9 months 
in the TARE group and 14.0 months in the TACE group. 
Table 1 Comparison of clinical characteristics
TARE group (n=16) TACE group (n=16) P
Male:female 15:1 13:3 0.593
Age [years] 55 [37-73] 62.5 [48-78] 0.067
Follow-up (months) 12.0 (2.3-52.5) 8.3 (2.9-41.1) 1
Child-Pugh class (%) 1
A 15 (93.8) 14 (87.5)
B 1 (6.3) 2 (12.5)
HBsAg positive (%) 12 (75.0) 13 (81.3) 1
Carrier of hepatitis C virus (%) 0 3 (27.3) 0.387
Alpha-fetoprotein [ng/mL] 38 [4-8,312] 242.5 [3-7,957] 0.323
ICG15 15.3 (7.4-55.7) 10 (6-62.9) 0.622
Albumin [g/L] 40 [26-47] 36.5 [21-45] 0.171
Creatinine [μmol/L] 81 [59-129] 77.5 [69-105] 0.926
Platelet count [×109] 163 [67-549] 171.5 [51-384] 0.897
International normalized ratio 1.1 (0.9-1.4) 1.1 (1-1.4) 0.381
Total bilirubin [μmol/L] 10 [5-28] 15 [8-34] 0.119
Aspartate transaminase [U/L] 69.5 [29-513] 77 [31-644] 0.590
Alanine transaminase [U/L] 64.5 [31-194] 47 [25-200] 0.445
Hemoglobin (g/dL) 12.65 (9.4-16.6) 12 (8.5-14.6) 0.149
No. of patients with comorbidity (%) 6 (37.5) 7 (43.8) 0.719
Cardiovascular disease (%) 5 (31.3) 6 (37.5) 1
Pulmonary disease (%) 0 1 (6.3) 1
Renal impairment (%) 0 0 1
Diabetes mellitus (%) 3 (18.8) 3 (18.8) 1
Gastrointestinal disease 0 2 (12.5) 0.465
Pretreatment MELD score 7.5 [6-12] 8.5 [6-12] 0.061
Data are shown in medians with ranges or numbers with percentages. ICG15, indocyanine green retention rate at 15 minutes; 
MELD, model for end-stage liver disease; TARE, transarterial radioembolization; TACE, transarterial chemoembolization.
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Table 2 Comparison of tumor characteristics
TARE group (n=16) TACE group (n=16) P
Tumor size (cm) 8.4 (2.5-22) 8.0 (1.5-21.2) 0.897
Tumor number (%) 0.532
One 7 (43.8) 6 (37.5)
Two 1 (6.3) 0
Three 1 (6.3) 3 (18.8)
Four 0 1 (6.3)
More than four 7 (43.8) 6 (37.5)
Tumor number 2.5 (1-multiple) 3 (1-multiple) 0.926
Absence of invasion of a major branch of the portal or hepatic vein (%) 8 (50.0) 8 (50.0) 1
Presence of invasion of a major branch of the portal or hepatic vein (%) 8 (50.0) 8 (50.0) –
Percentage of shunting 6.6 (3.4-16.1) – –
Tumor to normal liver count ratio 3.8 (0.32-11) – –
Portal vein involvement (%) 8 (50.0) 0 –
Data are shown in medians with ranges or numbers with percentages.
Table 3 Comparison of treatment responses
TARE group (n=16) TACE group (n=16) P
Tumor response (%) 0.632
Complete response 0 0
Partial response 4 (25.0) 2 (12.5)
Stable disease 5 (31.3) 5 (31.3)
Progress disease 7 (43.8) 9 (56.3)
Hospital mortality (%) 0 0 –
No. of patients with complication (%) 1 (6.3) 0 1
Severe ascites requiring tapping 1 0
The 3-year overall survival rate was 20.3% in the former 
and 9.7% in the latter (P=0.615) (Figure 1). Subgroup 
analyses of overall survival of patients who had and had not 
major vascular invasion were performed and comparisons 
were made between the TARE and TACE groups. In the 
subgroup with presence of major vascular invasion, patients 
in the TARE group had a median survival duration of 
12.0 months and a 2-year survival rate of 15.6%, whereas 
their counterparts had a median survival duration of 
8.0 months and a 1-year survival rate of 35% (P=0.664) 
(Figure 2). In the subgroup with absence of major vascular 
invasion, patients in the TARE group had a median 
survival duration of 21.2 months and a 3-year survival rate 
of 50.0%, whereas their counterparts had a median survival 
duration of 19.8 months and a 3-year survival rate of 15.0% 
(P=0.370) (Figure 3).
Discussion
HCC poses a common surgical problem in Asia. The 
etiological factors in Asian patients are different from those 
in Western patients. In Asian patients, chronic hepatitis B 
infection is the most common cause of HCC. Most of them 
present late with advanced disease and poor liver function 
associated with cirrhosis, which leave them with limited 
treatment choices. These patients cannot undergo liver 
transplantation or liver resection due to their advanced tumor 
status and poor liver function. The majority of patients with 
unresectable HCC are treated by various palliative therapies, 
such as TACE and TARE. External beam radiation therapy 
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has been shown to cause objective response and promising 
palliative effects (23-25). However, it is associated with 
significant morbidities, and there are technical difficulties 
associated with the delivery of radiation in a breathing 
subject (26). TARE aims to deliver adequate radiation doses 
to the tumor while keeping the level of toxicity affecting the 
functional liver parenchyma at the minimum and preserving 
the blood flow of the target area (27,28).
The present study excluded patients who had advanced 
tumors with extrahepatic metastases or main portal vein 
thrombosis (the most common vascular contraindication) 
and patients who had poor liver function, because TARE 
and TACE might further worsen their liver function and 
might even cause liver failure and death.
A previous study by our center had shown that TACE 
has a significant role in the management of patients with 
unresectable advanced HCC (4). In the present study, we 
used TACE as a standard treatment for patients who had 
unresectable HCC but no contraindication and compared 
its effectiveness with that of TARE using yttrium-90. The 
TARE group had a partial response rate of 25%, versus 
12.5% in the TACE group. The difference did not reach 
statistical significance, probably because of the limitation 
posed by the small number of patients. Further studies with 
patient cohorts large enough are required to investigate 
whether this increase in partial response will subsequently 
translate into any survival benefit.
Patients who were identified to undergo TARE were 
subjected to MAA screening and hepatic angiography to 
uncover their vascular anatomy and to identify the most 
suitable approach, i.e., the unilobar or the bilobar treatment 
approach, for them. Unfortunately, because of the potential 
radiotoxicity of the shunting effect, arteriovenous shunting of 
more than 20% was regarded as a contraindication to TARE.
There was no difference between the two groups in 
terms of side effects, and TARE was found to be safe, 
causing no significant immediate side effect. It has been 
found that TARE, unlike TACE, does not have a significant 
embolic effect in the hepatic arterial distribution (19). 
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Figure 1 Overall survival of all patients in the two groups. 
TARE, transarterial radioembolization; TACE, transarterial 
chemoembolization. 
Figure 3 Overall survival of patients without major vascular 
invasion in the two groups. TARE, transarterial radioembolization; 
TACE, transarterial chemoembolization.
Figure 2 Overall survival of patients with major vascular invasion 
in the two groups. TARE, transarterial radioembolization; TACE, 
transarterial chemoembolization. 
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On the other hand, TACE may result in some significant 
adverse reactions, which may turn into contraindications 
to subsequent TACE treatment (29,30). TARE could be 
an alternative treatment option for patients with advanced 
unresectable HCC, especially those unsuitable for TACE 
(13,31-36).
The present study adopted mRECIST as the assessment 
guidelines since their validity had been confirmed by various 
studies (37,38). Recently functional metabolic assessment 
was studied. While contrast computed tomography and 
magnetic resonance imaging can provide anatomical and 
vascular information, positron emission tomography can 
provide metabolic assessment for predicting treatment 
prognosis and response (39,40). This may help to reduce 
errors in anatomical measurement, which is relatively 
subjective as compared to measurement done by positron 
emission tomography. It has been shown that higher 
standardized uptake value ratios correlate with higher rates 
of response to external beam radiotherapy (41). Thus the 
use of positron emission tomography may be beneficial 
for selecting patients who are likely to respond to external 
radiotherapy. Given the limited life expectancy of HCC 
patients with portal vein tumor thrombus, it could help 
to select patients who are going to benefit the most from 
TARE. It could help to preclude unnecessary investigations 
and undesirable side effects of radiotherapy. Other forms of 
treatment, such as targeted therapy (e.g., sorafenib therapy) 
or best palliative care, would be considered instead.
This is a retrospective study with a small sample size. 
Although patients with major vascular involvement were 
seen to have prolonged survival, statistical significance was 
not demonstrated due to the small sample size. Randomized 
controlled trials would be helpful to minimize the bias. 
With an increasing number of patients receiving TARE, 
more data are being collected, allowing more convincing 
results in the future.
Conclusions 
In conclusion, patients with unresectable HCC have limited 
treatment options. While TACE is a well-established palliative 
treatment, TARE using yttrium-90 resin microspheres is a 
relatively new option. It might have a promising treatment 
effect, particularly in patients with major vascular involvement.
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